Drugs / NH280105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06870058 | Mar → Nov 2025 | Alzheimer disease | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NH280105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06870058 ↗ |
| Route | Oral | “Dose formulation: Capsule Route of administration: oral” NCT06870058 ↗ |